Ardent Health Partners (ARDT) Stock Forecast & Price Target

$19.19

-0.39 (-1.99%)

(As of 09/6/2024 ET)

Ardent Health Partners - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 11 Analyst Ratings

Based on 11 Wall Street analysts who have issued ratings for Ardent Health Partners in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for ARDT.

Consensus Price Target

$21.70
13.08% Upside

High Forecast	$27.00
Average Forecast	$21.70
Low Forecast	$18.00

According to the 11 analysts' twelve-month price targets for Ardent Health Partners, the average price target is $21.70. The highest price target for ARDT is $27.00, while the lowest price target for ARDT is $18.00. The average price target represents a forecasted upside of 13.08% from the current price of $19.19.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	N/A	N/A	N/A
Strong Buy	1 Strong Buy rating(s)	N/A	N/A	N/A
Buy	9 Buy rating(s)	N/A	N/A	N/A
Hold	1 Hold rating(s)	N/A	N/A	N/A
Sell	0 Sell rating(s)	N/A	N/A	N/A
Consensus Price Target	$21.70	N/A	N/A	N/A
Forecasted Upside	13.08% Upside	N/A	N/A	N/A

Get Ardent Health Partners Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARDT and its competitors with MarketBeat's FREE daily newsletter.

Ad Timothy Sykes

Tim Sykes’ Urgent Trade Alert: “Make this move now”

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

ARDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ardent Health Partners Stock vs. The Competition

Type	Ardent Health Partners	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.08% Upside	1,207.57% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/12/2024	Leerink Partnrs 0 of 5 stars	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2024	Bank of America 4 of 5 stars		Initiated Coverage	Buy	$22.00	+40.66%
8/12/2024	Loop Capital 2 of 5 stars	T. Greaves Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$18.00 ➝ $18.00	+15.09%
8/12/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fidel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$24.00 ➝ $24.00	+53.45%
8/12/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Cassorla Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00	+34.27%
8/12/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Hendrix Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$23.00	+47.06%
8/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$27.00	+72.63%
8/12/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$18.00	+15.09%
8/12/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00	+27.88%
8/12/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$23.00	+47.06%
8/12/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00 ➝ $21.00	+34.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:10 PM ET.

ARDT Forecast - Frequently Asked Questions

What is Ardent Health Partners' forecast for 2024?: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Ardent Health Partners is $21.70, with a high forecast of $27.00 and a low forecast of $18.00.
Should I buy or sell Ardent Health Partners stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardent Health Partners in the last year. There is currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDT shares.
Does Ardent Health Partners's stock price have much upside?: According to analysts, Ardent Health Partners's stock has a predicted upside of 38.75% based on their 12-month stock forecasts.
Has Ardent Health Partners been upgraded by Wall Street analysts recently?: Over the previous 90 days, Ardent Health Partners's stock had 1 upgrade by analysts.
What analysts cover Ardent Health Partners?: Ardent Health Partners has been rated by research analysts at Bank of America, Citigroup, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Loop Capital, Mizuho, Morgan Stanley, Royal Bank of Canada, Stephens, and Truist Financial in the past 90 days.
Do Wall Street analysts like Ardent Health Partners more than its competitors?: Analysts like Ardent Health Partners more than other "medical" companies. The consensus rating for Ardent Health Partners is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARDT compares to other companies.